Portland, OR -- (SBWIRE) -- 07/21/2017 -- Protein kinase is an enzyme that shuffles protein structure by transferring phosphate collected from ATP(Adenosine Triphosphate) . Protein kinase help in regulating variety of cell functions such as cell cycle, cell differentiation, cell proliferation and apoptosis. These cell processes are used in regulating various cell activities in cancer. The global inhibitors market was valued at approximately $105 billion. Increase in incident of cancer diseases is driving the growth for kinase inhibitor market. According to American Cancer Society, there were more than 1,660,290 new cases diagnosed in 2013. This shows potential for kinase inhibitors in cancer therapies. The growth of kinase inhibitor market is hindered by cost of treatment and lack of funds in conducting research. For Example, the cost of TKI (Tyrosin kinase inhibitors) was approximately $26,400 in non-pharmaceutical spending in 2012.
"Early Buyers Will Receive 20% Customization on This Report."
Increase in clinical trials for commercialization of kinase inhibitors in cancer treatment is facing challenges due to strict government regulations. However, an increase in investment from pharmaceutical companies is promoting the growth for kinase inhibitor market. This report provides an in depth analysis of clinical development and reimbursement strategies adopted by respective governments.
Get PDF Brochure @ https://www.alliedmarketresearch.com/request-toc-and-sample/167
Key companies include in the report are Bristol-Myers Squibb, Boehringer Ingelheim, Cytrx Corporation, Eisai Inc. Eton Bioscience Inc., Glaxosmithkline, Merck Serono Sa, Novartis International Ag, Osi Pharmaceuticals Llc, Pfizer.